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Purpose: The prevalence of activated protein C resistance (APCR) and associated throm- 
boric morbidity among patients who undergo arterial reconstruction were investigated. 
Methods: Preoperative assays for functional APCR and factor V (Leiden) mutation were 
performed on 262 patients who underwent arterial reconstructions that consisted of 
cerebrovascular surgery (109), aortic or iliofemoral procedures (76), or infrainguinal 
bypass procedures (77). Patients were monitored for thrombotic omplications during 
the postoperative p riod. 
Results: Depending on the stringency of the definition used, functional APCR was 
detected in 10.6% to 22.0% of patients tested. Factor V (Leiden) was found in 5.3% of 
patients. Thrombotic morbidity consisting of myocardial infarction, cerebrovascular 
event, or graft thrombosis occurred in 9.9% of patients, who were followed-up for a mean 
of 4.8 months. No significant overall correlations were found between APCR and 
thrombotic morbidity. Subgroup analysis revealed significant associations between func- 
tional APCR and total early postoperative thrombotic omplications and early graft 
failure, and between factor V (Leiden) and early cerebrovascular events and late graft 
thrombosis (p < 0.03). 
Conclusions: Functional APCR is somewhat more prevalent among general vascular 
surgical patients than in the general population, but factor V (Leiden) is no more 
prevalent. APCR is not a prominent cause of thrombotic morbidity in contemporary 
vascular surgery. Nonetheless, it is a sufficiently important potential contributor to 
morbidity among some subgroups to warrant selective testing and directed therapy 
pending further study. (J Vasc Surg 1997;25:1054-60.) 
The impact of hypercoagulable states on patients 
who have vascular disease is becoming clearer as 
progress is made in defining new entities. Most re- 
cently, patients have been found who have impair- 
ment of the natural anticoagulant function of acti- 
vated protein C. Individuals who have functional 
activated protein C resistance (F-APCR) fail to have 
in vitro evidence of anticoagulation i the presence 
of exogenous activated protein C despite adequate 
levels of normal protein C)  ,2 Most of  these subjects 
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appear to have an inborn error of metabolism that 
consists of a single site mutation and results in abnor- 
mal factor V (Leiden) that is resistant to proteolysis 
by activated protein C?  ,4 
The prevalence of F-APCR in the general popu- 
lation is 3.6% to 6%, and the prevalence of factor V 
(Leiden) is 2% to 10%. 5-s F-APCR has been found in 
an average of 22% of  patients who have precocious or 
recurrent venous thrombosis, and factor V (Leiden) 
is present in an average of 17% of such patients. 8 
There is conflicting evidence regarding the preva- 
lence of F-APCR and factor V (Leiden) among pa- 
tients with arterial disease. Furthermore, the poten- 
tial impact of these abnormalities on morbidity rates 
after peripheral vascular surgery remains to be fully 
investigated. 
PAT IENTS AND METHODS 
Between December 1994 and August 1996, 262 
patients were studied prospectively. All patients who 
had manifestations of arterial disease and who were 
scheduled for elective surgical reconstruction were 
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eligible. For purposes of analysis, the study group 
was divided into diagnostic categories of cerebrovas- 
cular, aortic aneurysm, and lower extremity occlusive 
disease and into the therapeutic categories of cere- 
brovascular, large-vessel (aortoiliofemoral), and 
small-vessel (infrainguinal) reconstructions. Choice 
of category was determined by presenting illness and 
procedure, with no patient being included in more 
than one category. Among 109 patients who under- 
went cerebrovascular surgery, 72 were asymptom- 
atic. Large-vessel reconstructions were performed in 
43 patients who had asymptomatic aortic aneurysms 
and in 33 patients who had aortoiliac occlusive dis- 
ease; 17 of these had claudication and 16 had critical 
ischemia. Among the 77 small-vessel reconstruc- 
tions, all used autogenous bypass grafts for claudica- 
tion in 18 instances and critical ischemia in 59. Pre- 
vious vascular reconstructions had been performed in
63 of the study patients (24%). 
The operative technique and the use of antiplate- 
let and anticoagulant medications were not affected 
by the study findings and followed standard clinical 
protocol. Adjunctive antithrombotic medications 
were prescribed at discharge after 91% ofcerebrovas- 
cular, 74% of large-vessel, and 84% of small-vessel 
procedures. Aspirin (81 to 325 rag/day) alone was 
recommended in 87%, warfarin (International Normal- 
ized Ratio, 2.5 to 3.0) alone in 10%, and aspirin in 
combination with warfarin in 3% of medicated patients. 
Patients were monitored at regular intervals after sur- 
gery during a mean follow-up of 4.8 months (range, 
0.1 to 19.0 months). Particular attention was directed 
at thrombotic omplications, which were defined as 
myocardial infarction, cerebrovascular events, venous 
thromboembolism, and reconstruction cclusion. 
Study patients underwent assay for F-APCR and 
factor V (I~iden) within 2 weeks before surgery. For 
F-APCR assay, venous blood was collected in citrate 
and was centrifuged to obtain plasma. The activated 
partial thromboplastin time (aPTT) was tested on 
patient samples and on samples from a pool of nor- 
mal subjects at the time of the assay. The aPTT test 
was repeated with the normal pool, with the addition 
of a sufficient quantity of human activated protein C 
(APC; Hematologic Technologies, Inc., Essex Junc- 
tion, Vt.) to prolong the baseline aPTT to 100 to 
160 seconds. This amount of human APC was added 
to each of the patient samples. A sensitivity ratio was 
then calculated from the aPTT with added APC 
divided by the aPTT without added APC. A normal- 
ized sensitivity ratio (NSR) was calculated by divid- 
ing the sensitivity ratio for each patient by the sensi- 
tivity ratio of the pool of normal subjects. Forty-four 
(16.8%) of the study patients were not tested with 
the functional assay because of known concurrent 
treatment with heparin or oral anticoagulants or
findings of elevated prothrombin time or aPTT be- 
fore the addition of APC. Four of these patients had 
evidence of lupus anticoagulant. 
Polymerase chain reaction (PCR) analysis fol- 
lowed by endonuclease digestion was used in all 
study patients to detect factor V (Leiden). A 267 
base pair (bp) region of the factor V gene was ampli- 
fied by PCR with primers PR-6967 and PR-990. 3 
The PCR reaction, performed on 200 ng samples of 
patient DNA, was carried out in a Perldn Elmer 
Cetus model 9600 thermal cycler, as previously de- 
scribed. 9DNA was initially denatured at94 ° C for 4 
minutes, then underwent 35 cycles of amplification 
with denaturation at 94 ° C for 20 seconds, annealing 
for 20 seconds with sequential 1° decreases in the 
annealing temperature from 65 ° C to 55 ° C during 
cycles 1 to 11, with all subsequent annealing at 
55 ° C. After 35 cycles, samples were incubated at 
72 ° C for 10 minutes and then cooled to 4 ° C for 5 
minutes. Control samples included water, normal 
DNA, RS06Q (factor V Leiden) heterozygote DNA, 
and R506Q homozygote DNA. Fifteen-microliter 
samples of PCR reactions were digested with restric- 
tion endonuclease Mnl I and were electrophoresed in 
2.5% agarose gels containing 0.3 txg/ml ethidium 
bromide. The genotype of each patient was deter- 
mined from the pattern of restriction fragments ob- 
served in the gel: the RS06Q factor V allele produces 
Mnl I fragments of 67 bp and 200 bp, whereas the 
normal factor V allele produces Mnl I fragments of 
37 bp, 67 bp, and 163 bp. 
Statistical analysis was performed correlating as- 
sociations between presence of F-APCR and factor V 
(Leiden) and thrombotic events using the ×2 or Fish- 
er's exact tests as appropriate. Significance was as- 
sumed with p levels less than 0.05. Because contro- 
versy remains regarding the definition of the cutoff 
value for abnormality, simultaneous analysis was per- 
formed for patients with NSR values lower than 0.70 
and lower than 0.80,10'11 emphasizing comparisons 
using the more stringently abnormal value of 0.70. 
The power of the sample size to exclude a type II 
error was calculated to be 90% in the overall group of 
262 patients. For the 218 patients who had F-APCR 
assay, the power was 86% for NSR values lower than 
0.70 and 93% for NSR values lower than 0.80. 
RESULTS 
The distribution of NSR values for all 218 pa- 
tients who were tested for F-APCR is shown in Fig. 
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Fig. 1. Histogram shows distribution of NSR values 
among 218 study patients tested for F-APCR @ray bars). 
Mean value is 1.06 --- 0.32. Values that occur in subset of 
12 tested patients with factor V (Leiden) mutation are 
shown in black, all lower than 0.66. Distribution of the 20 
tested patients among 26 patients with thrombotic mor- 
bidity is at top of graph, by number falling into each gray 
bar. 
1. F-APCR was present in 23 (10.6%) of the tested 
patients using a definition of NSR values lower than 
0.70 and in 48 (22.0%) using NSRvalues lower than 
0.80. Heterozygosity for factor V (Leiden) was de- 
tected in 14 patients (5.3%), with a maximal NSR 
value of 0.66 (mean, 0.52 + 0.09; range, 0.36 to 
0.66) among the 12 tested for F-APCR. Assuming 
the two untested mutants had NSRvalues lower than 
0.80 and omitting the other 42 patients who did not 
have F-APCR assay from the analysis, factor V (Lei- 
den) explained APCR in at most 56% of patients who 
had NSRvalues lower thab 0.70 and 28% of patients 
who had NSR values lower than 0.80 (Table I). No 
homozygous mutants were detected. 
Analysis of the distribution of abnormalities 
among the three diagnostic ategories of patients 
demonstrated a nearly significant (p = 0.056) in- 
crease in prevalence among patients who had lower 
extremity occlusive disease using an NSR value lower 
than 0.70 and demonstrated a highly significant in- 
crease using a ratio lower than 0.80 (p < 0.001; 
Table II). There was no significant association be- 
tween F-APCR and factor V (Leiden) and sex (p > 
0.19), patients who had disease at less than 50 years 
of age (p > 0.28), use ofantithrombotic medications 
at discharge (p > 0.23), or patients who had under- 
Table I. Correlation of F-APCR with factor 
V (Leiden) 
Factor V+ Factor V-  Total 
NSR* < 0.80 14" 36 50 
NSR < 0.70 14" 11 25 
NSR > 0.80 0 170 170 
NSR > 0.70 0 195 195 
Total 14 206 220* 
*Analysis excludes 42 patients not tested for F-APCR and includes 
two patients not tested for F-APCR who were factor V+ with 
assumption that hey had NSR < 0.80 (see text). 
gone previous arterial reconstructive procedures (p > 
0.32). Coincidental screening revealed heparin-in- 
duced platelet activation (HIPA) in 13 (5.0%) and 
evidence ofantiphospholipid antibodies (APA) in 14 
(5.4%) of the study patients. No patients who had 
HIPA had factor V (Leiden), and none of the 12 
tested for F-APCR had NSR values lower than 0.80. 
Three of 10 patients with APA who were tested for 
F-APCR had NSRvalues lower than 0.80, and one of 
these also had factor V (Leiden). 
Early thrombotic morbidity occurred in 10 pa- 
tients (3.8%) within 30 days of surgery (Table III). 
Three myocardial infarctions followed carotid endar- 
terectomy (1) and aortoiliac reconstruction (2). One 
stroke and one transient ischemic attack followed 
carotid endarterectomy performed for symptoms, 
and one transient attack occurred after the 72 carotid 
procedures performed in asymptomatic patients. 
Four graft occlusions followed autogenous infrain- 
guinal bypass, three of which had infrapopliteal distal 
anastomoses. Operative death occurred in two pa- 
tients (0.7%), both ofmultisystem organ failure after 
thoracoabdominal aneurysm resection. No deaths 
occurred among the patients who underwent cere- 
brovascular or peripheral vascular reconstruction. 
During postoperative follow-up, 16 additional 
(6.1%) late thrombotic events occurred, including 
one myocardial infarction, four strokes, and 11 late 
primary graft occlusions (Table III). Two of the four 
strokes occurred in patients who were known to have 
carotid disease. Nine of the occluded bypass grafts 
were infrainguinal, all with anastomoses into tibial or 
pedal arteries. Late death occurred in seven patients, 
unrelated to thrombotic events in the six in whom a 
cause was established. No deep venous thrombosis 
(DVT) was encountered. 
The distribution of patients with thrombotic 
morbidity by NSR is shown in Fig. 1. Combined 
thrombotic morbidity occurred in five (21.7%) of the 
23 patients with NSRs lower than 0.70 and in two 
(14.3%) of the 14 with factor V (Leiden), with no 
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Table II. Prevalence of APCR by diagnostic ategory 
Functional APCR 
Category n Mean NSR %< O. 70 %< O. 80 
Factor V (Leiden) 
n %+ 
Cerebrovascular 92 1.12 + 0.32 9.2 13.8 
Aortic aneurysm 34 1.16 + 0.32 2.3 7.0 
Lower occlusive 92 0.98 +_ 0.31 10.9" 27.3 t 
Total 218 1.06 +- 0.32 10.6 22.0 
109 6.4 
43 2.3 
110 5.5 
262 5.3 
*p = 0.056, X 2. 
I"P < 0.001, ×2. 
Table III. Thrombotic morbidity after revascularization, bytherapeutic category (%) 
Myocardial 
infarction Stroke: TIA 
Therapeutic 
category (n) Early Late Early Late 
Graft 
occlusion 
Early Late 
Cerebrovascular (109) 1 (0.9) 0 1:2 (2.7) 2:0 (1.8) 
Large vessel (76) 2 (2.6) 1 (1.3) 0 1:0 (1.3) 
Small vessel (77) 0 0 0 1:0 (1.3) 
Total (262) 3 (1.1) 1 (0.4) 1:2 (1.1) 4:0 (1.5) 
0 0 
0 2 (2.6) 
4 (5.2) 9 (11.7) 
4 (1.5) 11 (4.2) 
significant association between morbidity and either 
measure ofAPCR (p > 0.12) (Table IV). Analysis of 
all study patients by morbidity subgroup revealed an 
association between F-APCR and both early throm- 
botic complications of all types (p = 0.0007) and 
early graft occlusions (p = 0.01). Factor V (Leiden) 
was associated with both early postoperative c rebro- 
vascular event (p = 0.03) and with late graft occlu- 
sion (p = 0.02). Analysis of each therapeutic cate- 
gory revealed no correlations between APCR and 
morbidity except a significant association between 
F-APCR and total early thrombotic morbidity (p = 
0.03) and early myocardial infarction (p = 0.004) 
among patients who had cerebrovascular surgery. 
These findings were not significantly altered by re- 
peat analysis to include all patients with NSRs lower 
than 0.80, among whom combined thrombotic mor- 
bidity occurred in six instances (12.5%). Three pa- 
tients with APA and one with HIPA had thrombotic 
morbidity. The single patient who had both APA and 
factor V (Leiden) had late infrainguinal graft occlu- 
sion. 
DISCUSSION 
Hypercoagulability has been implicated as an im- 
portant contributor to vascular thrombosis for many 
years but remains the most elusive component of 
Virchow's classic triad. 8,12 Recently, significant 
progress has been made by the discovery that a rela- 
tively large number of patients have APCR, an im- 
portant form of hereditary hypercoagulability that 
results in decreased efficacy of the natural anticoagu- 
lant protein C. 2 From the outset, APCR has been 
detected by in vitro functional assay, which uses a 
sensitivity ratio to express the relative change in 
aPTT before and after addition of APC to plasma. 
The present study used this assay, normalized against 
pooled normal plasma, 11 which explains sensitivity 
ratio values that differ from other investigators. 2,13-~s 
An NSR of 0.84 was found to be two standard 
deviations lower than the normal value among 100 
apparently healthy subjects? The prevalence of F- 
APCR in the general population has been estimated 
at 3.6% to 6%. 8 It was subsequently found a that a 
mutation in factor V (factor V R506Q Leiden) is 
responsible for the majority of cases ,of 
F-APCR.  6'11'16 The mutant gene is inherited in an 
autosomal dominant pattern, with a prevalence of 2% 
to 10% of the general population. 5,6,8 APC renders 
the clotting cascade inoperative by lysing activated 
factor V, and the mutant form of factor V is relatively 
resistant to binding and inactivation. 
Despite improvements in F-APCR assay methods 
and reporting standards, 11the definition of abnormal 
and the degree to which factor V (Leiden) explains 
the abnormality remain unclear. An analysis of 370 
patients at Brigham & Women's Hospital revealed 
that no patients who had factor V (Leiden) had an 
NSR greater than 0.71 (mean, 0.49 _+ 0.09), l° 
which is similar to the value of 0.66 that was found in 
the present study and a value of 0.70 that has been 
found by others) 1 Despite ratios lower than 0.71 
being 100% sensitive for factor V (Leiden), the spec- 
ificity was 87% in the Brigham study and at best 56% 
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Table IV. Association between APCR and postoperative thrombotic morbidity in 262 study patients 
Functional APCR * Factor V (Leiden) 
Morbidity (n) n (%) p? n (%) p? 
Total (26) 6 (23) 0.12 3 (11.5) 0.57 
Early (10) 4 (40) 0.0007 1 (10) 0.50 
Late (16) 2 (12.5) 0.48 2 (12.5) 0.16 
Myocardial infarction (4) 1 (25) 0.34 0 0.63 
Early (3) 1 (33) 0.20 0 0.68 
Late (1) 0 0.73 0 0.81 
Cerebrovascular event (7) 2 (28.5) 0.07 1 (14) 0.36 
Early (3) 1 (33) 0.07 1 (33) 0.03 
Late (4) 1 (25) 0.34 0 0.59 
Graft occlusion (15) 3 (20) 0.07 2 (13) 0.09 
Early (4) 2 (50) 0.01 0 0.63 
Late (11) 1 (9) 0.74 2 (18) 0.02 
*Normalized sensitivity ratio <0.70. 
~×2 or Fisher's exact est as appropriate. 
for the current series. The molecular basis of F- 
APCR in the remaining patients who had NSRs 
lower than 0.70 without factor V (Leiden) and in 
those who had NSRs between 0.70 and the pur- 
ported value of 0.84 for the lower limit of normal is 
unclear. Whether genetic, acquired, or method- 
ologic, elucidation of other mechanisms that cause 
faulty APC dynamics must await further work in the 
absence of convincing data in the literature. 
As in other hypercoagulable states that are related 
to clotting and regulatory protein abnormalities, the 
thrombotic manifestations of APCR surface most 
prominently in the venous ystem. 7,17 Indeed, APCR 
is the most prevalent hypercoagulable state yet to be 
associated with venous thrombosis. A recent litera- 
ture review indicated the presence of F-APCR in 21% 
of nonselected patients with DVT and in an average 
of 22% (10% to 64%) of patients with DVT who were 
younger than 45 years of age or had had previous 
DVT. 8 An average frequency of 17% (11% to 37%) 
for factor V (Leiden) was reported for the latter 
group. Homozygotes for factor V (Leiden) were 
found to have an 80-fold increase in DVT, generally 
at a young age, and heterozygotes had a sevenfold 
increase) 8 Although APCR results in relative crip- 
pling of the natural anticoagulant effect of protein C, 
it is not commonly sufficiently strong to create 
thrombosis without coincident risk factors being 
present. 5 Indeed, a venous thrombotic multiplier ef- 
fect has been found among patients in whom a com- 
bination of APCR with other natural anticoagulant 
deficiencies, s with pregnancy, or with oral contracep- 
fives, 9 is present. 
Evidence that APCR may have a strong acceler- 
ant role in arterial disease is suggested by a report of 
F-APCR in six (20%) of 30 patients who had stroke 
at a young age) 9 On the other hand, another study 
of patients who had precocious arterial disease found 
a normal prevalence of F-APCR of only 4.5%, 2° and 
the present series was unable to associate APCR with 
age less than 50 years, suggesting that other factors 
are more responsible for causing arterial athero- 
thrombosis in this complicated subgroup. It is rea- 
sonable to hypothesize that APCR may not contrib- 
ute to the pathophysiologic mechanism of arterial 
disease until slowly progressive diffuse atherosclerosis 
evolves with age to the point of terminal thrombosis 
and causes a sufficiently overt clinical event to 
prompt vascular surgical consultation. In support is 
the finding that thrombotic events occur at a later 
age in the presence of APCR than in its absence 
among patients with arterial disease 14 and the ten- 
dency in the present series toward a higher preva- 
lence of APCR among patients who had occlusive 
disease compared with those who had aneurysms. 
The prevalence and importance of APCR in the 
generally older population of patients with arterial 
disease has been unclear. A study of 1408 male mem- 
bers of the Physicians' Health Study found no differ- 
ence in prevalence of factor V (Leiden) in subjects 
who had had myocardial infarction or stroke (6.1% 
and 4.3%, respectively) compared with matched ap- 
parently healthy subjects (6.0%) and the general pop- 
ulation. 7 On the other hand, a recent report found 
F-APCR in 11.6% of 173 patients who had vascular 
disease and disproportionately among 13.7% of a 
subgroup of 95 patients who had lower extremity 
occlusive disease.14 Among 76 reported patients who 
underwent infrainguinal bypass, 29% had graft occlu- 
sion over a mean 47-month follow-up, including 6 of 
10 (60%) with F-APCR compared with only 16 of 66  
(24%) without F-APCR (p = 0.02). Furthermore, 
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likely anatomic explanatory lesions for the failure 
were found in 79% of the normal patients and in only 
20% of the APCR group. This study did not include 
analysis for factor V (Leiden). 
The present series is a continuation ofa previous 
report on general vascular surgical patients who were 
studied prospectively to document the prevalence of 
various hypercoagulable states. 21 Depending on the 
degree of protein C resistance used in the definition 
of abnormality, F-APCR was found in 10.6% to 
22.0% of subjects. The prevalence of F-APCR in this 
group of vascular surgical patients was thus some- 
what higher than in the general population but less 
than that which has been found in patients who have 
venous thromboembolic disease. The suggestive in- 
crease in prevalence among patients who have lower 
extremity occlusive disease is in agreement with find- 
ings of other investigators 14 and supports the conclu- 
sion that F-APCR may exert a contributing influence 
in the pathogenesis of terminal arterial thromboem- 
bolism. Factor V (Leiden) was detected in only 5.3% 
of the study group, a prevalence similar to that of the 
general population, which suggests at best a weak 
role for this form of APCR in the pathogenesis of
arterial disease. 7 The apparent distinctions between 
F-APCR and factor V (Leiden) in this regard should 
stimulate renewed inquiry into alternative mecha- 
f 
nisms for F-APCR. 
The present findings associating APCR with a 
14% to 22% risk of combined postoperative throm- 
boric morbidity of all types did not reach statistical 
significance. A significant association with graft oc- 
clusion was noted when all of the study patients were 
analyzed together. Thirteen of the 15 occlusions 
were in infrainguinal grafts, which suggests with Ou- 
riel et al. 14 that such grafts may be particularly vul- 
nerable in the presence of APCR, despite the lack of 
confirmatory statistical power from analysis of the 
group of small vessel reconstructions alone. Indeed, 
analysis of all subgroups was subject o type II statis- 
tical error because of the small numbers of events, 
despite the large size of the overall study population. 
Conclusions drawn fi'om this and future studies 
would be strengthened not only by larger numbers 
but by a longer follow-up period, inclusion of life- 
long individual and family arterial and venous throm- 
botic morbidity data, and controls for important 
variables uch as concurrent illness, other hyperco- 
agulable states, and antithromboric agents. Further 
investigation should focus on homogeneous high- 
risk problem patients, uch as those who have recur- 
rent infrainguinal thromboses, rather than on 
broader heterogeneous populations. 
CONCLUSION 
A clinical program ofrourine preoperative screen- 
ing for APCR in the general vascular population who 
undergo elective arterial reconstructive surgery can 
be expected to reveal abnormalities somewhat more 
frequently than for the general population. APCR 
may influence postoperative thrombotic morbidity in 
some patients, but the overall impact appears to be 
rclarively weak or largely ameliorated by current 
techniques in vascular surgery. Pending further in- 
vestigation, it is reasonable to test selected patients, 
such as those who are to undergo infrainguinal by- 
pass to distal vessels, and to consider the adjunctive 
use of anticoagulant therapy when abnormality is
detected. 
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